Aligos Therapeutics (ALGS) Competitors $7.95 +0.64 (+8.76%) Closing price 07/3/2025 02:52 PM EasternExtended Trading$7.76 -0.19 (-2.39%) As of 07/3/2025 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. TLSA, TIL, OGI, CYBN, NVCT, SPRO, NLTX, IPHA, LRMR, and ALTSShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Tiziana Life Sciences (TLSA), Instil Bio (TIL), Organigram Global (OGI), Cybin (CYBN), Nuvectis Pharma (NVCT), Spero Therapeutics (SPRO), Neoleukin Therapeutics (NLTX), Innate Pharma (IPHA), Larimar Therapeutics (LRMR), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Tiziana Life Sciences Instil Bio Organigram Global Cybin Nuvectis Pharma Spero Therapeutics Neoleukin Therapeutics Innate Pharma Larimar Therapeutics ALT5 Sigma Tiziana Life Sciences (NASDAQ:TLSA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations. Do institutionals & insiders hold more shares of TLSA or ALGS? 60.4% of Aligos Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TLSA or ALGS more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Tiziana Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Aligos Therapeutics -1,628.75%14.67%7.19% Does the media favor TLSA or ALGS? In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score. Company Overall Sentiment Tiziana Life Sciences Neutral Aligos Therapeutics Neutral Which has higher earnings and valuation, TLSA or ALGS? Tiziana Life Sciences has higher earnings, but lower revenue than Aligos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$11.86MN/AN/AAligos Therapeutics$3.94M12.33-$131.21M-$17.51-0.45 Do analysts rate TLSA or ALGS? Aligos Therapeutics has a consensus price target of $70.00, indicating a potential upside of 780.50%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, TLSA or ALGS? Tiziana Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. SummaryAligos Therapeutics beats Tiziana Life Sciences on 8 of the 11 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.57M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.09%P/E Ratio-0.4521.5627.4720.28Price / Sales12.33244.81408.30121.41Price / CashN/A41.9536.6357.47Price / Book-1.067.518.095.67Net Income-$131.21M-$55.05M$3.17B$248.96M7 Day Performance10.26%4.61%2.82%3.30%1 Month Performance26.39%4.89%3.69%5.20%1 Year Performance-24.73%5.84%35.42%21.37% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.7862 of 5 stars$7.95+8.8%$70.00+780.5%-24.7%$48.57M$3.94M-0.4590TLSATiziana Life Sciences0.7052 of 5 stars$1.55-0.6%N/A+86.7%$182.28MN/A0.008TILInstil Bio2.6285 of 5 stars$29.84+7.7%$119.00+298.8%+176.2%$181.68MN/A-2.49410News CoverageOGIOrganigram Global0.6811 of 5 stars$1.28-0.8%N/A-10.7%$172.78M$117.47M12.80860CYBNCybin2.7381 of 5 stars$7.41-4.8%$86.00+1,060.6%N/A$170.39MN/A-1.6950News CoverageAnalyst RevisionNVCTNuvectis Pharma2.6957 of 5 stars$7.96-2.1%$17.00+113.6%+24.2%$169.86MN/A-7.048SPROSpero Therapeutics3.9304 of 5 stars$2.93-3.0%$5.00+70.6%+119.6%$168.85M$47.98M-2.29150NLTXNeoleukin TherapeuticsN/A$17.76-3.0%N/A-45.1%$166.91MN/A-5.7190High Trading VolumeIPHAInnate Pharma2.5884 of 5 stars$1.80flat$11.00+511.1%-15.3%$165.92M$21.77M0.00220Gap DownLRMRLarimar Therapeutics1.8043 of 5 stars$2.42-6.6%$19.67+712.7%-58.8%$165.83MN/A-1.6230Gap UpHigh Trading VolumeALTSALT5 Sigma0.1281 of 5 stars$9.13-3.6%N/AN/A$165.21M$12.53M0.00170News Coverage Related Companies and Tools Related Companies Tiziana Life Sciences Competitors Instil Bio Competitors Organigram Global Competitors Cybin Competitors Nuvectis Pharma Competitors Spero Therapeutics Competitors Neoleukin Therapeutics Competitors Innate Pharma Competitors Larimar Therapeutics Competitors ALT5 Sigma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
